These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 28683599)

  • 1. Response letter to SEJ Todd et al. - Early clinical experience of dolutegravir in an HIV cohort in a larger teaching hospital.
    Eisner M; Fernandez C; Michie K; Thomson-Glover R; Chaponda M; Ratcliffe L
    Int J STD AIDS; 2017 Sep; 28(10):1051-1052. PubMed ID: 28683599
    [No Abstract]   [Full Text] [Related]  

  • 2. Early clinical experience of dolutegravir in an HIV cohort in a larger teaching hospital.
    Todd S; Rafferty P; Walker E; Hunter M; Dinsmore WW; Donnelly CM; McCarty EJ; Quah SP; Emerson CR
    Int J STD AIDS; 2017 Oct; 28(11):1074-1081. PubMed ID: 28118801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dolutegravir in HIV-2-Infected Patients With Resistant Virus to First-line Integrase Inhibitors From the French Named Patient Program.
    Descamps D; Peytavin G; Visseaux B; Tubiana R; Damond F; Campa P; Charpentier C; Khuong-Josses MA; Duvivier C; Karmochkine M; Lukiana T; Matheron S
    Clin Infect Dis; 2015 May; 60(10):1521-7. PubMed ID: 25690598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discontinuation of treatment and adverse events in an Italian cohort of patients on dolutegravir.
    Bonfanti P; Madeddu G; Gulminetti R; Squillace N; Orofino G; Vitiello P; Rusconi S; Celesia BM; Maggi P; Ricci E;
    AIDS; 2017 Jan; 31(3):455-457. PubMed ID: 28079544
    [No Abstract]   [Full Text] [Related]  

  • 5. [Dolutegravir (Tivicay) orally].
    J Pharm Belg; 2015 Sep; (3):47-8. PubMed ID: 26513835
    [No Abstract]   [Full Text] [Related]  

  • 6. Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV.
    Kandel CE; Walmsley SL
    Drug Des Devel Ther; 2015; 9():3547-55. PubMed ID: 26185421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.
    Cahn P; Pozniak AL; Mingrone H; Shuldyakov A; Brites C; Andrade-Villanueva JF; Richmond G; Buendia CB; Fourie J; Ramgopal M; Hagins D; Felizarta F; Madruga J; Reuter T; Newman T; Small CB; Lombaard J; Grinsztejn B; Dorey D; Underwood M; Griffith S; Min S;
    Lancet; 2013 Aug; 382(9893):700-8. PubMed ID: 23830355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dolutegravir, a second-generation integrase inhibitor for the treatment of HIV-1 infection.
    Rathbun RC; Lockhart SM; Miller MM; Liedtke MD
    Ann Pharmacother; 2014 Mar; 48(3):395-403. PubMed ID: 24259658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dolutegravir intensification and HIV persistence: 3 + 1 = 3.
    Henrich TJ
    Lancet HIV; 2018 May; 5(5):e201-e202. PubMed ID: 29643012
    [No Abstract]   [Full Text] [Related]  

  • 10. Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response.
    Requena S; Treviño A; Cabezas T; Garcia-Delgado R; Amengual MJ; Lozano AB; Peñaranda M; Fernández JM; Soriano V; de Mendoza C;
    J Antimicrob Chemother; 2017 Jul; 72(7):2083-2088. PubMed ID: 28369593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dolutegravir for treatment of HIV: SPRING forwards?
    Waters LJ; Barber TJ
    Lancet; 2013 Mar; 381(9868):705-6. PubMed ID: 23306001
    [No Abstract]   [Full Text] [Related]  

  • 12. [Integrase inhibitor in HIV therapy. Does dolutegravir set new standards?].
    MMW Fortschr Med; 2014 Jun; 156 Suppl 1():58-9. PubMed ID: 25026862
    [No Abstract]   [Full Text] [Related]  

  • 13. [Efficacy of dolutegravir in treatment-experienced patients: the SAILING and VIKING trials].
    Moreno S; Berenguer J
    Enferm Infecc Microbiol Clin; 2015 Mar; 33 Suppl 1():26-30. PubMed ID: 25858609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV - an alternative viewpoint.
    Gillette MA; Shah BM; Schafer JJ; DeSimone JA
    Pharmacotherapy; 2014 Sep; 34(9):e173-4. PubMed ID: 25182330
    [No Abstract]   [Full Text] [Related]  

  • 15. Dolutegravir (Tivicay) for HIV infection.
    Rhyne DN; Byrd ES; Klibanov OM
    Nurse Pract; 2014 Jun; 39(6):11-5. PubMed ID: 24841459
    [No Abstract]   [Full Text] [Related]  

  • 16. Dolutegravir--a promising antiretroviral in development.
    Boyd M
    Lancet Infect Dis; 2012 Feb; 12(2):90-1. PubMed ID: 22018759
    [No Abstract]   [Full Text] [Related]  

  • 17. Dolutegravir maintains a durable effect against HIV replication in tissue culture even after drug washout.
    Osman N; Mesplède T; Quashie PK; Oliveira M; Zanichelli V; Wainberg MA
    J Antimicrob Chemother; 2015 Oct; 70(10):2810-5. PubMed ID: 26142476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance.
    Hardy I; Brenner B; Quashie P; Thomas R; Petropoulos C; Huang W; Moisi D; Wainberg MA; Roger M
    J Antimicrob Chemother; 2015 Feb; 70(2):405-11. PubMed ID: 25281399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuropsychiatric events and dolutegravir in HIV patients: a worldwide issue involving a class effect.
    Kheloufi F; Boucherie Q; Blin O; Micallef J
    AIDS; 2017 Jul; 31(12):1775-1777. PubMed ID: 28700395
    [No Abstract]   [Full Text] [Related]  

  • 20. Might dolutegravir be part of a functional cure for HIV?
    Wainberg MA; Han YS; Mesplède T
    Can J Microbiol; 2016 May; 62(5):375-82. PubMed ID: 27031127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.